Interleukin-21 surface-modified MB49 cell vaccine for treatment of metastatic bladder in mice.
- Author:
Junming PENG
1
;
Xiaojun SHI
;
Dingnan CHEN
;
Zhongkun LIANG
;
Kaijian LAN
;
Jimin GAO
;
Wanlong TAN
Author Information
- Publication Type:Journal Article
- MeSH: Amino Acid Motifs; Animals; Cancer Vaccines; therapeutic use; Cell Line, Tumor; Female; Immunotherapy; Interleukins; immunology; Lymphocyte Activation; Mice; Mice, Inbred C57BL; Neoplasm Metastasis; Neoplasms, Experimental; therapy; T-Lymphocytes, Cytotoxic; immunology; Urinary Bladder Neoplasms; therapy
- From: Journal of Southern Medical University 2012;32(6):807-811
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVETo develop a novel vaccine by immobilizing interleukin-21 (IL-21) on the surface of MB49 cells and evaluate its effect in inducing specific cytotoxic T lymphocytes (CTLs) and antitumor immunity in a mouse model of subcutaneous metastatic bladder cancer.
METHODSSA-IL-21 was immobilized on the surface of 30% ethanol-fixed MB49 cells to prepare the cell vaccine. C57BL/6 mice with subcutaneous implantation of MB49 bladder cancer cells were randomized into 5 groups to receive treatments with IL-21/MB49 vaccine, soluble IL-21, GFP surface-modified MB49 cells, ethanol-fixed MB49 cells, or PBS. The tumor growth and CTL were examined to assess the antitumor efficacy of the vaccine.
RESULTSIL-21 surface-modified MB49 cell vaccine significantly inhibited the tumor growth and generated a long-lasting memory response (P<0.05). At the same effector-target (E:T) ratio, the specific CTLs induced by IL-21/MB49 vaccine showed the most potent cytotoxicity against MB49 cells (P<0.05).
CONCLUSIONWith the protein-anchor technique, IL-21 can be efficiently immobilized on the surface of MB49 cells to prepare IL-21/MB49 cells vaccine. The novel vaccine can maintain its biological activity and significantly enhance the cytotoxicity of CTLs against bladder cancer cells.
